• Company
• 2 CGRP Migraine New Drugs
• by Eo, Yun-Ho Jan 6, 2023 05:57am

• Company
• Phase 1 of HLB Apixaban was approved
• by Lee, Seok-Jun Jan 6, 2023 05:56am

• Policy
• Termination of PVA research services
• by Lee, Tak-Sun Jan 6, 2023 05:56am

• Company
• Celltrion Remsima is licensed in 100 countries
• by Kim, Jin-Gu Jan 6, 2023 05:56am

• Company
• Bayer and Boryung are competing in the aspirin market
• by Nho, Byung Chul Jan 4, 2023 05:32am

• Company
• Will Tagrisso finally be reimb in the 1st line after 4 yrs?
• by Eo, Yun-Ho Jan 4, 2023 05:32am

• Policy
• Approval of Pfizer’s JAK inhibitor Xeljanz Srup imminent
• by Lee, Hye-Kyung Jan 4, 2023 05:32am

• Company
• ablbio will receive 32 billion won in technical fee
• by Jan 4, 2023 05:32am

• Company
• CTLA-4 inhibitor Imjudo is expected to commercialize
• by Eo, Yun-Ho Jan 4, 2023 05:32am

• Policy
• Koselugo is the only non-reimbursed drug among 21
• by Lee, Tak-Sun Jan 3, 2023 05:41am